Sign In
Buy IMUX
$13.97
-0.0200 (-0.143%)
At Close: Jul 31, 2026
Immunic advances Phase 3 MS program, eyes topline data by year-end
09:18am, Wednesday, 13'th May 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Wednesday it remains on track to deliver top-line phase 3 data for its lead multiple sclerosis drug candidate, vidofludimus calcium, by the end of 2026, as
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
06:30am, Wednesday, 13'th May 2026
– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D.
Immunic advances Phase 3 MS program, eyes topline data by year-end
05:04am, Wednesday, 13'th May 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Wednesday it remains on track to deliver top-line phase 3 data for its lead multiple sclerosis drug candidate,...
Immunic: Saved By A 200 Million Private Placement
11:48am, Tuesday, 12'th May 2026
Immunic, Inc. (IMUX) is rated Hold due to high cash burn, heavy dilution, and reliance on a single near-term catalyst. Vidofludimus calcium (IMU-838) Phase 3 MS trial results, expected late 2026, are
Immunic to Participate in Investor and Medical Conferences in May
06:30am, Thursday, 30'th Apr 2026
NEW YORK, April 30, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announce
Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout
08:43am, Tuesday, 28'th Apr 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Michael A. Panzara as Chief Medical Officer, bringing aboard a veteran neurologist with more than 25 years of drug development experience as the biotechno
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.
06:30am, Tuesday, 28'th Apr 2026
– Proven Leader in Neurology Drug Development, Including for Several Approved MultipleSclerosis Therapies – – Strong Experience in Advancing Late-Stage Clinical Programs and Obtaining Global Reg
Immunic to implement 1-for-10 reverse stock split
08:54am, Thursday, 23'rd Apr 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced it will implement a 1-for-10 reverse stock split of its common shares, effective April 27, as part of efforts to meet contractual obligations tied to a re
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
08:00am, Thursday, 23'rd Apr 2026
NEW YORK, April 23, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the "Company" or
ServiceNow shares fall as growth and margin concerns weigh on outlook
05:44am, Thursday, 23'rd Apr 2026
ServiceNow Inc (NYSE:NOW, XETRA:4S0) reported in-line to better-than-expected first quarter results, but concerns over growth trends and margins weighed on...
Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says
02:20pm, Friday, 17'th Apr 2026
Stifel on Thursday initiated coverage on Immunic Inc. (NASDAQ: IMUX), a late-stage biotechnology company developing oral therapies for neurologic and gastrointestinal diseases.
Immunic to Participate in Scientific and Medical Conferences in April
06:30am, Thursday, 09'th Apr 2026
NEW YORK, April 9, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced
Immunic to present lead MS therapy at April conferences
05:31am, Thursday, 09'th Apr 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said it will participate in two April conferences. At the Neuroimmunology Drug Development Summit (Apr. 14–16, Boston),...
Nasdaq leads markets lower as Iran says 'restraint is ended' ahead of Trump deadline
07:09am, Tuesday, 07'th Apr 2026
11:05am: 'Wait and see' Axel Rudolph, chief technical analyst at IG, notes that traders are largely adopting a wait‑and‑see approach as Trump’s deadline for...
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
06:30am, Wednesday, 01'st Apr 2026
NEW YORK, April 1, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced
